04:45 PM EDT, 03/24/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to $331 from $304 based on our Net Present Value (NPV) analysis. We lower our 2025 EPS estimate to -$1.62 from $0.30 our 2026 EPS estimate to $3.08 from $3.59. We continue to be bullish on shares of Alnylam following the recent successful FDA approval of the company key RNAi therapy (Amvuttra) for a supplemental New Drug Application (sNDA) to treat cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations, and urgent heart failure visits. The approval is a solid win for ALNY as it allows indication expansion for Amvuttra. We expect to see a solid uptake for new patients in the U.S. as Amvuttra becomes the only approved therapeutic drug to address Cardiomyopathy and Polyneuropathy Manifestations of ATTR Amyloidosis at the same time. According to ALNY, ATTR-CM, a fast progressing and fatal disease, impacts 150K patients in the U.S. and over 300K worldwide.